These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2755275)

  • 21. Bioavailability assessment of vitamin A self-nanoemulsified drug delivery systems in rats: a comparative study.
    Taha E; Ghorab D; Zaghloul AA
    Med Princ Pract; 2007; 16(5):355-9. PubMed ID: 17709923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single dose pharmacokinetics of ciclosporin and its main metabolites after oral ciclosporin as oily solution or capsule.
    Bleck JS; Nashan B; Christians U; Schottmann R; Wonigeit K; Sewing KF
    Arzneimittelforschung; 1990 Jan; 40(1):62-4. PubMed ID: 2340002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of PFA (trisodium phosphonoformate) after i.v. and p.o. administration to beagle dogs and rabbits.
    Ritschel WA; Grummich KW; Hussain SA
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):41-8. PubMed ID: 3157841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics and relative bioavailability of probucol inclusion complex capsule in healthy dogs].
    Zhang Z; Chen BL; Wang K; Huang YL; Fang SQ; Gu DL; Fang L; Han SJ
    Yao Xue Xue Bao; 2002 Mar; 37(3):210-3. PubMed ID: 12579765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human.
    Wu Y; Loper A; Landis E; Hettrick L; Novak L; Lynn K; Chen C; Thompson K; Higgins R; Batra U; Shelukar S; Kwei G; Storey D
    Int J Pharm; 2004 Nov; 285(1-2):135-46. PubMed ID: 15488686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
    Kiriyama A; Sugahara M; Yoshikawa Y; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Mar; 17(2):125-34. PubMed ID: 8907719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absorption and disposition of SDZ IMM 125, a new cyclosporine derivative, in rats after single and repeated administration.
    Bruelisauer A; Kawai R; Misslin P; Lemaire M
    Drug Metab Dispos; 1994; 22(2):194-9. PubMed ID: 8013274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioavailability of nifedipine from different oral dosage forms in healthy volunteers.
    Leucuţa SE; Vida-Simiti L; Căprioară MG; Făgărăşan E; Olinic N; Manasia M; Vlaicu R
    Pharmazie; 1989 May; 44(5):336-8. PubMed ID: 2772014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of an azopolymer based colonic release capsule for delivering proteins/macromolecules.
    Cheng CL; Gehrke SH; Ritschel WA
    Methods Find Exp Clin Pharmacol; 1994 May; 16(4):271-8. PubMed ID: 8051987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel gels and their dispersions--oral drug delivery systems for ciclosporin.
    Murdan S; Andrýsek T; Son D
    Int J Pharm; 2005 Aug; 300(1-2):113-24. PubMed ID: 16009515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers.
    Piñeyro-López A; Piñeyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez-Silva M; Waksman N; E Salazar-Leal M; Luján-Rangel R
    Clin Ther; 2007 Sep; 29(9):2049-54. PubMed ID: 18035203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.
    Shen H; Zhong M
    J Pharm Pharmacol; 2006 Sep; 58(9):1183-91. PubMed ID: 16945176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation.
    Han SF; Yao TT; Zhang XX; Gan L; Zhu C; Yu HZ; Gan Y
    Int J Pharm; 2009 Sep; 379(1):18-24. PubMed ID: 19508887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an in vitro/in vivo correlation for lipid formulations of EMD 50733, a poorly soluble, lipophilic drug substance.
    Schamp K; Schreder SA; Dressman J
    Eur J Pharm Biopharm; 2006 Apr; 62(3):227-34. PubMed ID: 16246538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclosporin A blood levels during use of cyclosporin as oral solution or in capsules: comparison of pharmacokinetic parameters.
    Hilbrands LB; Hoitsma AJ; van den Berg JW; Koene RA
    Transpl Int; 1991 Jun; 4(2):125-7. PubMed ID: 1910430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a lipoidic excipient on the absorption profile of compound UK 81252 in dogs after oral administration.
    Chang RK; Shojaei AH
    J Pharm Pharm Sci; 2004 Jan; 7(1):8-12. PubMed ID: 15144729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of particle size on bioavailability in cyclosporine preparations based on submicron dispersions.
    Vrána A; Andrýsek T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):9-15. PubMed ID: 12426767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
    Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
    Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil.
    Mariño EL; Dominguez-Gil A; Muriel C
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):73-7. PubMed ID: 7061182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part II: Quantifying its pharmacokinetic variability and refining the bioavailability estimate.
    Kovarik JM; Mueller EA; Richard F; Tetzloff W
    J Clin Pharmacol; 1997 Nov; 37(11):1009-14. PubMed ID: 9505993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.